151
|
Coxon FP. An update on the pharmacology of bisphosphonates and analogues with lower bone affinity. ACTA ACUST UNITED AC 2008. [DOI: 10.1138/20080341] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
152
|
Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008; 34:453-75. [PMID: 18423992 DOI: 10.1016/j.ctrv.2008.02.004] [Citation(s) in RCA: 160] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2008] [Revised: 02/28/2008] [Accepted: 02/28/2008] [Indexed: 12/13/2022]
Abstract
Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and are firmly established in the management of breast cancer patients with metastatic skeletal disease. There are extensive data that bisphosphonates, particularly nitrogen-containing bisphosphonates such as zoledronic acid, exhibit anti-tumour activity potentially via both indirect and direct mechanisms in vitro. In vivo studies using animal models of breast cancer induced bone disease have shown that bisphosphonates exert anti-tumour effects via inhibiting osteolysis and reducing skeletal tumour burden. Furthermore, pre-clinical studies have demonstrated synergistic anti-tumour effects between chemotherapy agents commonly used in breast cancer treatment and nitrogen-containing bisphosphonates. This, coupled with emerging evidence from pre-clinical in vivo studies suggesting that bisphosphonates may have additional anti-tumour activity outside of the bone microenvironment, could be of significant importance in the clinical management of breast cancer. The evidence in favour of an anti-tumour effect of bisphosphonates in the clinical setting is inconclusive however, with conflicting evidence from several trials. This review focuses on the anti-tumour activity of bisphosphonates in breast cancer, with particular focus on zoledronic acid. The pre-clinical evidence for anti-tumour activity will be reviewed, followed by the synergistic effects with anti-cancer agents. Finally, the clinical relevance and strategies for the evaluation of anti-tumour activity in breast cancer will be discussed. We are currently exploring the potential synergistic anti-tumour effects of the sequential treatment of neoadjuvant chemotherapy followed by zoledronic acid in a randomised phase II study evaluating biological endpoints including apoptosis, proliferation and angiogenesis in patients with breast cancer.
Collapse
Affiliation(s)
- M C Winter
- Academic Unit of Clinical Oncology, Section for Cancer, Cancer Research Centre, University of Sheffield, Weston Park Hospital, Sheffield S10 2SJ, UK.
| | | | | |
Collapse
|
153
|
Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19:733-59. [PMID: 18214569 DOI: 10.1007/s00198-007-0540-8] [Citation(s) in RCA: 946] [Impact Index Per Article: 59.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2007] [Accepted: 11/27/2007] [Indexed: 12/12/2022]
Abstract
UNLABELLED Bisphosphonates (BPs) are well established as the leading drugs for the treatment of osteoporosis. There is new knowledge about how they work. The differences that exist among individual BPs in terms of mineral binding and biochemical actions may explain differences in their clinical behavior and effectiveness. INTRODUCTION The classical pharmacological effects of bisphosphonates (BPs) appear to be the result of two key properties: their affinity for bone mineral and their inhibitory effects on osteoclasts. DISCUSSION There is new information about both properties. Mineral binding affinities differ among the clinically used BPs and may influence their differential distribution within bone, their biological potency, and their duration of action. The antiresorptive effects of the nitrogen-containing BPs (including alendronate, risedronate, ibandronate, and zoledronate) appear to result from their inhibition of the enzyme farnesyl pyrophosphate synthase (FPPS) in osteoclasts. FPPS is a key enzyme in the mevalonate pathway, which generates isoprenoid lipids utilized for the post-translational modification of small GTP-binding proteins that are essential for osteoclast function. Effects on other cellular targets, such as osteocytes, may also be important. BPs share several common properties as a drug class. However, as with other families of drugs, there are obvious chemical, biochemical, and pharmacological differences among the individual BPs. Each BP has a unique profile that may help to explain potential clinical differences among them, in terms of their speed and duration of action, and effects on fracture reduction.
Collapse
Affiliation(s)
- R G G Russell
- Nuffield Department of Orthopaedic Surgery, Oxford University Institute of Musculoskeletal Sciences (The Botnar Research Centre), Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, UK.
| | | | | | | |
Collapse
|
154
|
Deprèle S, Kashemirov BA, Hogan JM, Ebetino FH, Barnett BL, Evdokimov A, McKenna CE. Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): Synthetic, structural, and modeling studies. Bioorg Med Chem Lett 2008; 18:2878-82. [DOI: 10.1016/j.bmcl.2008.03.088] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2008] [Revised: 03/22/2008] [Accepted: 03/31/2008] [Indexed: 11/24/2022]
|
155
|
Mukherjee P, Desai PV, Srivastava A, Tekwani BL, Avery MA. Probing the structures of leishmanial farnesyl pyrophosphate synthases: homology modeling and docking studies. J Chem Inf Model 2008; 48:1026-40. [PMID: 18419114 DOI: 10.1021/ci700355z] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Leishmania donovani and Leishmania major farnesyl pyrophosphate synthase ( LdFPPS and LmFPPS) are potential targets for the development of antileishmanial therapy. The protein sequence for LdFPPS was recently elucidated in our laboratory. Highly refined homology models were generated using the protein sequences of LdFPPS and the closely related LmFPPS enzyme. A ligand-refined model of LmFPPS with a bound bisphosphonate ligand was generated using restraint-guided molecular mechanics followed by quantum mechanics/molecular mechanics refinement. The ligand-refined model of LmFPPS was further validated through extensive pose validation, enrichment, and other docking studies involving known bisphosphonate inhibitors. The model was able to explain the critical binding site interactions and site-directed mutagenesis data obtained from experimental studies on related FPPS enzymes. The ligand-refined model in conjunction with the validated docking protocol could be utilized in the future for structure-based virtual screening and rational drug design studies against these targets.
Collapse
Affiliation(s)
- Prasenjit Mukherjee
- Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, Mississippi 38677, USA
| | | | | | | | | |
Collapse
|
156
|
Dunford JE, Kwaasi AA, Rogers MJ, Barnett BL, Ebetino FH, Russell RGG, Oppermann U, Kavanagh KL. Structure–Activity Relationships Among the Nitrogen Containing Bisphosphonates in Clinical Use and Other Analogues: Time-Dependent Inhibition of Human Farnesyl Pyrophosphate Synthase. J Med Chem 2008; 51:2187-95. [DOI: 10.1021/jm7015733] [Citation(s) in RCA: 124] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- James E. Dunford
- Structural Genomics Consortium, The Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom, Nuffield Department of Orthopaedic Surgery, The Botnar Research Centre, University of Oxford, Institute of Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, United Kingdom, Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom, Chemistry Department, University of Cincinnati,
| | - Aaron A. Kwaasi
- Structural Genomics Consortium, The Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom, Nuffield Department of Orthopaedic Surgery, The Botnar Research Centre, University of Oxford, Institute of Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, United Kingdom, Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom, Chemistry Department, University of Cincinnati,
| | - Michael J. Rogers
- Structural Genomics Consortium, The Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom, Nuffield Department of Orthopaedic Surgery, The Botnar Research Centre, University of Oxford, Institute of Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, United Kingdom, Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom, Chemistry Department, University of Cincinnati,
| | - Bobby L. Barnett
- Structural Genomics Consortium, The Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom, Nuffield Department of Orthopaedic Surgery, The Botnar Research Centre, University of Oxford, Institute of Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, United Kingdom, Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom, Chemistry Department, University of Cincinnati,
| | - Frank H. Ebetino
- Structural Genomics Consortium, The Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom, Nuffield Department of Orthopaedic Surgery, The Botnar Research Centre, University of Oxford, Institute of Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, United Kingdom, Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom, Chemistry Department, University of Cincinnati,
| | - R. Graham G. Russell
- Structural Genomics Consortium, The Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom, Nuffield Department of Orthopaedic Surgery, The Botnar Research Centre, University of Oxford, Institute of Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, United Kingdom, Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom, Chemistry Department, University of Cincinnati,
| | - Udo Oppermann
- Structural Genomics Consortium, The Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom, Nuffield Department of Orthopaedic Surgery, The Botnar Research Centre, University of Oxford, Institute of Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, United Kingdom, Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom, Chemistry Department, University of Cincinnati,
| | - Kathryn L. Kavanagh
- Structural Genomics Consortium, The Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom, Nuffield Department of Orthopaedic Surgery, The Botnar Research Centre, University of Oxford, Institute of Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, United Kingdom, Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom, Chemistry Department, University of Cincinnati,
| |
Collapse
|
157
|
Peukert S, Sun Y, Zhang R, Hurley B, Sabio M, Shen X, Gray C, Dzink-Fox J, Tao J, Cebula R, Wattanasin S. Design and structure-activity relationships of potent and selective inhibitors of undecaprenyl pyrophosphate synthase (UPPS): tetramic, tetronic acids and dihydropyridin-2-ones. Bioorg Med Chem Lett 2008; 18:1840-4. [PMID: 18295483 DOI: 10.1016/j.bmcl.2008.02.009] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2008] [Accepted: 02/07/2008] [Indexed: 11/29/2022]
Abstract
Based on a pharmacophore hypothesis substituted tetramic and tetronic acid 3-carboxamides as well as dihydropyridin-2-one-3-carboxamides were investigated as inhibitors of undecaprenyl pyrophosphate synthase (UPPS) for use as novel antimicrobial agents. Synthesis and structure-activity relationship patterns for this class of compounds are discussed. Selectivity data and antibacterial activities for selected compounds are provided.
Collapse
Affiliation(s)
- Stefan Peukert
- Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
158
|
Saikia S, Nicholson MJ, Young C, Parker EJ, Scott B. The genetic basis for indole-diterpene chemical diversity in filamentous fungi. ACTA ACUST UNITED AC 2008; 112:184-99. [DOI: 10.1016/j.mycres.2007.06.015] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2007] [Revised: 05/24/2007] [Accepted: 06/19/2007] [Indexed: 10/23/2022]
|
159
|
Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J, Clézardin P. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007; 67:9894-902. [PMID: 17942921 DOI: 10.1158/0008-5472.can-06-3940] [Citation(s) in RCA: 149] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Osteoclasts mediate bone destruction in breast cancer skeletal metastases. Cathepsin K is a proteinase that is secreted by osteoclasts and degrades bone. Here, immunohistochemistry revealed that cathepsin K was expressed not only by osteoclasts but also by breast cancer cells that metastasize to bone. Following intratibial injection with cathepsin K-expressing human BT474 breast cancer cells, tumor-bearing mice treated with a clinical dosing regimen of cathepsin K inhibitor (CKI; 50 mg/kg, twice daily) had osteolytic lesions that were 79% smaller than those of tumor-bearing mice treated with the vehicle. The effect of CKI was also studied in a mouse model in which the i.v. inoculation of human B02 breast cancer cells expressing cathepsin K leads to bone metastasis formation. Drug administration was started before (preventive protocol) or after (treatment protocol) the occurrence of osteolytic lesions. In treatment protocols, CKI (50 mg/kg, twice daily) or a single clinical dose of 100 microg/kg zoledronic acid (osteoclast inhibitor) reduced the progression of osteolytic lesions by 59% to 66%. CKI therapy also reduced skeletal tumor burden by 62% compared with vehicle, whereas zoledronic acid did not decrease the tumor burden. The efficacy of CKI at inhibiting skeletal tumor burden was similar in the treatment and preventive protocols. By contrast, CKI did not block the growth of s.c. B02 tumor xenografts in animals. Thus, CKI may render the bone a less favorable microenvironment for tumor growth by inhibiting bone resorption. These findings raise the possibility that cathepsin K could be a therapeutic target for the treatment of bone metastases.
Collapse
Affiliation(s)
- Céline Le Gall
- Institut National de la Santé et de la Recherche Médicale, UMR 664, IFR62, Lyon, France
| | | | | | | | | | | | | | | |
Collapse
|
160
|
Sen SE, Trobaugh C, Béliveau C, Richard T, Cusson M. Cloning, expression and characterization of a dipteran farnesyl diphosphate synthase. INSECT BIOCHEMISTRY AND MOLECULAR BIOLOGY 2007; 37:1198-1206. [PMID: 17916506 DOI: 10.1016/j.ibmb.2007.07.011] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/04/2006] [Revised: 07/10/2007] [Accepted: 07/13/2007] [Indexed: 05/25/2023]
Abstract
Farnesyl diphosphate synthase (FPPS) of the dipteran Drosophila melanogaster has been cloned and its catalytic properties have been assessed. Analysis of the D. melanogaster genome and of ESTs indicates that FPPS is a single copy gene that produces two transcripts, which differ only by 5' extension. The cDNA of shorter and longer D. melanogaster FPPSs (DmFPPS-1a and DmFPPS-1b, respectively) were each subcloned into pET28a and expressed as an N-His6 fusion protein in BL21 E. coli cells. The DmFPPSs similarly catalyzed the coupling of the allylic substrates, GPP and DMAPP, with IPP, producing FPP as product. The longer protein was further characterized. The enzyme required divalent metal for activity, and was activated by 0.1% Triton X-100. Higher detergent concentration and the addition of glycerol, conditions that activate certain insect FPPSs, inhibited prenyl coupling by DmFPPS-1b. Although DmFPPS-1b does not efficiently couple homologous GPP compounds, homodimethylallyl diphosphate (HDMAPP), which is precursor to all homologous JH structures, was a reactive substrate.
Collapse
Affiliation(s)
- Stephanie E Sen
- Department of Chemistry, Indiana U.-Purdue U. Indianapolis (IUPUI), 402 North Blackford Street, Indianapolis, IN 46202, USA.
| | | | | | | | | |
Collapse
|
161
|
|
162
|
Wiemer AJ, Yu JS, Lamb KM, Hohl RJ, Wiemer DF. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorg Med Chem 2007; 16:390-9. [PMID: 17905588 DOI: 10.1016/j.bmc.2007.09.029] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2007] [Revised: 09/13/2007] [Accepted: 09/13/2007] [Indexed: 10/22/2022]
Abstract
Nitrogenous bisphosphonates are used clinically to reduce bone resorption associated with osteoporosis or metastatic bone disease, and are recognized as inhibitors of farnesyl diphosphate synthase. Inhibition of this enzyme decreases cellular levels of both farnesyl diphosphate and geranylgeranyl diphosphate which results in a variety of downstream biological effects including inhibition of protein geranylgeranylation. Our lab recently has prepared several isoprenoid bisphosphonates that inhibit protein geranylgeranylation and showed that one selectively inhibits geranylgeranyl diphosphate synthase. This results in depletion of intracellular geranylgeranyl diphosphate and impacts protein geranylgeranylation but does not affect protein farnesylation. To clarify the structural features of isoprenoid bisphosphonates that account for their geranylgeranyl diphosphate synthase inhibition, we have prepared a new group of isoprenoid bisphosphonates. The complete set of compounds has been tested for in vitro inhibition of human recombinant geranylgeranyl diphosphate synthase and cellular inhibition of protein geranylgeranylation. These results show some surprising relationships between in vitro and cellular activity, and will guide development of clinical agents directed at geranylgeranyl diphosphate synthase.
Collapse
Affiliation(s)
- Andrew J Wiemer
- Interdisciplinary Program in Molecular and Cellular Biology, University of Iowa, Iowa City, IA 52242-1294, USA
| | | | | | | | | |
Collapse
|
163
|
Mönkkönen H, Ottewell PD, Kuokkanen J, Mönkkönen J, Auriola S, Holen I. Zoledronic acid-induced IPP/ApppI production in vivo. Life Sci 2007; 81:1066-70. [PMID: 17850825 DOI: 10.1016/j.lfs.2007.08.007] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2007] [Revised: 06/24/2007] [Accepted: 08/06/2007] [Indexed: 11/25/2022]
Abstract
Bisphosphonates are currently the most important class of anti-resorptive drugs used for the treatment of diseases involving excess bone resorption. Recently we discovered a new mechanism of action for bisphosphonates. Previously it has been shown that nitrogen-containing bisphosphonates (N-BPs) are not metabolized. However, our studies revealed that N-BPs induce formation of a novel pro-apoptotic ATP analog (ApppI), as a consequence of the inhibition of FPP synthase in the mevalonate pathway, and the subsequent accumulation of isopentenyl pyrophosphate (IPP) in vitro. The primary aim of the current study was to determine whether zoledronic acid (a N-BP) induces IPP/ApppI formation in vivo. Mass spectrometry was used to identify whether in vivo administration of zoledronic acid-induced IPP/ApppI production by mouse peritoneal macrophages or bone marrow cells. IPP/ApppI could be detected in extracts from peritoneal macrophages isolated from zoledronic acid-treated animals. Increasing IPP/ApppI accumulation was determined up to 7 days after drug injection, indicating prolonged FPP synthase inhibition by zoledronic acid. Importantly, this is the first report of in vivo production of ApppI, supporting the biological significance of this molecule.
Collapse
|
164
|
Weiss HM, Wirz B, Schweitzer A, Amstutz R, Rodriguez Perez MI, Andres H, Metz Y, Gardiner J, Seebach D. ADME Investigations of Unnatural Peptides: Distribution of a14C-Labeledβ3-Octaarginine in Rats. Chem Biodivers 2007; 4:1413-37. [PMID: 17638323 DOI: 10.1002/cbdv.200790121] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The highly positively charged, cell-penetrating beta3-octaarginine has been prepared with a radioactive label by acetylation at the N-terminus with a doubly (14)C-labeled acetyl group ((14)CH3-(14)CO). With the radioactive compound, an ADME study (Absorption, Distribution, Metabolism, Excretion) was performed in male rats following an intravenous or oral dose of 1 mg/kg. Sampling was carried out after periods ranging from 5 min to 4 d or 7 d for blood/excretia and quantitative whole-body autoradioluminography (QWBA), respectively. After p.o. dosing, no systemic exposure to peptide-related radioactivity was observed, and the dose was completely excreted in the feces within 24 h suggesting the absence of relevant absorption; less than 3% of the i.v. dose was excreted from the animals within 4 d. Blood levels, after i.v. dosing, dropped within 4 d to less than 2% of Cmax and decreased afterwards only very slowly. No metabolites were observed in the systemic circulation. QWBA Data indicated that the distribution of the acetyl-beta-octaarginine-related radioactivity in the organs and tissues shifted over time. Notably, after 7 d, the highest concentration was measured in the lymph nodes, and the largest amount was found in the liver. A comparison with the results of two previous ADME investigations of beta-peptides (cf. Table 1) reveals that the distribution of the compounds within the animals is structure-dependent, and that there is a full range from oral availability with rather rapid excretion (of a tetrapeptide) to essentially complete lack of both oral absorption and excretion after i.v. administration (of a highly charged octapeptide). A discussion is presented about the in vivo stability and 'drug-ability' of peptides. In general, beta-peptides bearing proteinogenic side chains are compared with peptides consisting entirely of D-alpha-amino acid residues (the enantiomers of the 'natural' building blocks), and suggestions are made regarding a possible focus of future biomedical investigations with beta-peptides.
Collapse
Affiliation(s)
- H Markus Weiss
- Drug Metabolism and Pharmacokinetics, Novartis Pharma AG, Postfach, CH-4002 Basel
| | | | | | | | | | | | | | | | | |
Collapse
|
165
|
Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, Jeng WY, Chen CKM, Zhang Y, Song Y, Kuo CJ, Yin F, Oldfield E, Wang AHJ. Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A 2007; 104:10022-7. [PMID: 17535895 PMCID: PMC1877987 DOI: 10.1073/pnas.0702254104] [Citation(s) in RCA: 145] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Bisphosphonate drugs (e.g., Fosamax and Zometa) are thought to act primarily by inhibiting farnesyl diphosphate synthase (FPPS), resulting in decreased prenylation of small GTPases. Here, we show that some bisphosphonates can also inhibit geranylgeranyl diphosphate synthase (GGPPS), as well as undecaprenyl diphosphate synthase (UPPS), a cis-prenyltransferase of interest as a target for antibacterial therapy. Our results on GGPPS (10 structures) show that there are three bisphosphonate-binding sites, consisting of FPP or isopentenyl diphosphate substrate-binding sites together with a GGPP product- or inhibitor-binding site. In UPPS, there are a total of four binding sites (in five structures). These results are of general interest because they provide the first structures of GGPPS- and UPPS-inhibitor complexes, potentially important drug targets, in addition to revealing a remarkably broad spectrum of binding modes not seen in FPPS inhibition.
Collapse
Affiliation(s)
- Rey-Ting Guo
- *Taiwan International Graduate Program
- Institute of Biological Chemistry
- Core Facility for Protein Crystallography, Academia Sinica, Taipei 115, Taiwan
- Institute of Biochemical Sciences, National Taiwan University, Taipei 106, Taiwan
| | - Rong Cao
- Center for Biophysics and Computational Biology, University of Illinois at Urbana–Champaign, 607 South Mathews Avenue, Urbana, IL 61801; and
| | - Po-Huang Liang
- *Taiwan International Graduate Program
- Institute of Biological Chemistry
- Institute of Biochemical Sciences, National Taiwan University, Taipei 106, Taiwan
| | | | - Tao-Hsin Chang
- Core Facility for Protein Crystallography, Academia Sinica, Taipei 115, Taiwan
- Institute of Biochemical Sciences, National Taiwan University, Taipei 106, Taiwan
| | - Michael P. Hudock
- Center for Biophysics and Computational Biology, University of Illinois at Urbana–Champaign, 607 South Mathews Avenue, Urbana, IL 61801; and
| | - Wen-Yih Jeng
- Institute of Biological Chemistry
- Core Facility for Protein Crystallography, Academia Sinica, Taipei 115, Taiwan
| | - Cammy K.-M. Chen
- Institute of Biological Chemistry
- Institute of Biochemical Sciences, National Taiwan University, Taipei 106, Taiwan
| | - Yonghui Zhang
- Department of Chemistry, University of Illinois at Urbana–Champaign, 600 South Mathews Avenue, Urbana, IL 61801
| | - Yongcheng Song
- Department of Chemistry, University of Illinois at Urbana–Champaign, 600 South Mathews Avenue, Urbana, IL 61801
| | - Chih-Jung Kuo
- *Taiwan International Graduate Program
- Institute of Biological Chemistry
- Institute of Biochemical Sciences, National Taiwan University, Taipei 106, Taiwan
| | - Fenglin Yin
- Center for Biophysics and Computational Biology, University of Illinois at Urbana–Champaign, 607 South Mathews Avenue, Urbana, IL 61801; and
| | - Eric Oldfield
- Center for Biophysics and Computational Biology, University of Illinois at Urbana–Champaign, 607 South Mathews Avenue, Urbana, IL 61801; and
- Department of Chemistry, University of Illinois at Urbana–Champaign, 600 South Mathews Avenue, Urbana, IL 61801
- **To whom correspondence may be addressed. E-mail: or
| | - Andrew H.-J. Wang
- *Taiwan International Graduate Program
- Institute of Biological Chemistry
- Core Facility for Protein Crystallography, Academia Sinica, Taipei 115, Taiwan
- Institute of Biochemical Sciences, National Taiwan University, Taipei 106, Taiwan
- **To whom correspondence may be addressed. E-mail: or
| |
Collapse
|
166
|
Glickman JF, Schmid A. Farnesyl Pyrophosphate Synthase: Real-Time Kinetics and Inhibition by Nitrogen-Containing Bisphosphonates in a Scintillation Assay. Assay Drug Dev Technol 2007; 5:205-14. [PMID: 17477829 DOI: 10.1089/adt.2007.057] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
A mix-and-read FlashPlate (PerkinElmer, Waltham, MA) assay for the enzyme farnesyl pyrophosphate (FPP) synthase (FPPS) was developed to rapidly measure both steps in the synthesis of FPP from dimethylallyl pyrophosphate (DMAPP). The assay used either DMAPP or geranyl pyrophosphate (GPP) and [(3)H]isopentenyl pyrophosphate ([(3)H]IPP) as substrates, and measured the FPPS-catalyzed conversion of these into [(3)H]FPP or [(3)H]GPP by capturing the products onto a phospholipid-coated scintillating microtiter plate and monitoring the product formation in a charge coupled device imager. The Michaelis-Menten parameters-k(cat) GPP (38/min), K(m) IPP (0.6 microM), and K(m) GPP (0.7 microM)-were consistent with previous studies using difficult phase separation techniques. The 50% inhibitory concentrations of various nitrogen-containing bisphosphonates (N-BPs) were determined and were also consistent with prior literature. Without precedent, weaker inhibition (5 microM) of the non-N-BPs was also detected. In preincubation studies, the potency of the N-BPs, and specifically zoledronate, increased slowly over time by 100-fold. This potency shift was reversed significantly by the inclusion of GPP with zoledronate. Zoledronate was uncompetitive with respect to IPP. Thus, these studies were consistent with prior structural and thermodynamic studies, and suggest a rapid formation of a lower-affinity complex between zoledronate and the GPP binding site, followed by the formation of a very tight complex of zoledronate and enzyme, which excludes further binding of GPP. Furthermore, one of the substrates from the first step in the catalytic cycle, DMAPP, was identified as a 1 microM inhibitor of the second step of the catalysis, suggesting that the FPP two-step synthesis is regulated by DMAPP.
Collapse
Affiliation(s)
- J Fraser Glickman
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
| | | |
Collapse
|
167
|
Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev 2007; 215:59-76. [PMID: 17291279 DOI: 10.1111/j.1600-065x.2006.00479.x] [Citation(s) in RCA: 338] [Impact Index Per Article: 19.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Human Vgamma2Vdelta2 T cells play important roles in mediating immunity against microbial pathogens and have potent anti-tumor activity. Vgamma2Vdelta2 T cells recognize the pyrophosphorylated isoprenoid intermediates (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), an intermediate in the foreign 2-C-methyl-d-erythritol 4-phosphate (MEP) pathway, and isopentenyl pyrophosphate (IPP), an intermediate in the self-mevalonate pathway. Infection with bacteria and protozoa using the MEP pathway leads to the rapid expansion of Vgamma2Vdelta2 T cells to very high numbers through preferential recognition of HMBPP. Activated Vgamma2Vdelta2 T cells produce proinflammatory cytokines and chemokines, kill infected cells, secrete growth factors for epithelial cells, and present antigens to alphabeta T cells. Vgamma2Vdelta2 T cells can also recognize high levels of IPP in certain tumors and in cells treated with pharmacological agents, such as bisphosphonates and alkylamines, that block farnesyl pyrophosphate synthase. Activated Vgamma2Vdelta2 T cells are able to kill most tumor cells because of recognition by T-cell receptor and natural killer receptors. The ubiquitous nature of the antigens converts essentially all Vgamma2Vdelta2 T cells to memory cells at an early age. Thus, primary infections with HMBPP-producing bacteria are perceived by Vgamma2Vdelta2 T cells as a repeat infection. Extensive efforts are underway to harness these cells to treat a variety of cancers and to provide microbial immunity.
Collapse
Affiliation(s)
- Craig T Morita
- Division of Rheumatology, Department of Internal Medicine, Interdisciplinary Graduate Program in Immunology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA.
| | | | | | | |
Collapse
|
168
|
Maalouf MA, Wiemer AJ, Kuder CH, Hohl RJ, Wiemer DF. Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation. Bioorg Med Chem 2007; 15:1959-66. [PMID: 17254791 DOI: 10.1016/j.bmc.2007.01.002] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2006] [Revised: 11/21/2006] [Accepted: 01/01/2007] [Indexed: 10/23/2022]
Abstract
Geminal bisphosphonates can be used for a variety of purposes in human disease including reduction of bone resorption in osteoporosis, treatment of fractures associated with malignancies of the prostate, breast, and lung, and direct anticancer activity against bone marrow derived malignancies. Previous research led to identification of some novel isoprenoid bisphosphonates that inhibit geranylgeranyl pyrophosphate (GGPP) synthesis and diminish protein geranylgeranylation. Described here is the synthesis of fluorescent anthranilate analogues of the most active isoprenoid bisphosphonates and examine their ability to impact post-translational processing of the small GTPases Ras, Rap1a, and Rab6. Similar to their non-fluorescent counterparts, some of these fluorescent isoprenoid bisphosphonates diminish protein geranylgeranylation. Their biological activity and fluorescent character suggest that they may be useful in studies of bisphosphonate localization both in cultured cells and in whole organisms.
Collapse
Affiliation(s)
- Mona A Maalouf
- Department of Chemistry, University of Iowa, Iowa City, IA 52242-1294, USA
| | | | | | | | | |
Collapse
|
169
|
Wiemer AJ, Tong H, Swanson KM, Hohl RJ. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochem Biophys Res Commun 2006; 353:921-5. [PMID: 17208200 DOI: 10.1016/j.bbrc.2006.12.094] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2006] [Accepted: 12/09/2006] [Indexed: 11/22/2022]
Abstract
A primary cellular target of the clinical nitrogenous bisphosphonates is the isoprenoid biosynthetic pathway. Specifically these drugs inhibit the enzyme farnesyl pyrophosphate synthase and deplete cells of larger isoprenoids. Inhibition of this enzyme results in impaired processing of both farnesylated and geranylgeranylated proteins. We recently showed that isoprenoid-containing bisphosphonates such as digeranyl bisphosphonate inhibit protein geranylgeranylation and not farnesylation. Here, we show that this impairment results from potent and specific inhibition of geranylgeranyl pyrophosphate synthase, which leads to enhanced depletion of intracellular geranylgeranyl pyrophosphate relative to the nitrogenous bisphosphonate zoledronate.
Collapse
Affiliation(s)
- Andrew J Wiemer
- Molecular and Cellular Biology Interdisciplinary Program, Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
| | | | | | | |
Collapse
|
170
|
Masterjohn C. Vitamin D toxicity redefined: vitamin K and the molecular mechanism. Med Hypotheses 2006; 68:1026-34. [PMID: 17145139 DOI: 10.1016/j.mehy.2006.09.051] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2006] [Accepted: 09/14/2006] [Indexed: 11/18/2022]
Abstract
The dose of vitamin D that some researchers recommend as optimally therapeutic exceeds that officially recognized as safe by a factor of two; it is therefore important to determine the precise mechanism by which excessive doses of vitamin D exert toxicity so that physicians and other health care practitioners may understand how to use optimally therapeutic doses of this vitamin without the risk of adverse effects. Although the toxicity of vitamin D has conventionally been attributed to its induction of hypercalcemia, animal studies show that the toxic endpoints observed in response to hypervitaminosis D such as anorexia, lethargy, growth retardation, bone resorption, soft tissue calcification, and death can be dissociated from the hypercalcemia that usually accompanies them, demanding that an alternative explanation for the mechanism of vitamin D toxicity be developed. The hypothesis presented in this paper proposes the novel understanding that vitamin D exerts toxicity by inducing a deficiency of vitamin K. According to this model, vitamin D increases the expression of proteins whose activation depends on vitamin K-mediated carboxylation; as the demand for carboxylation increases, the pool of vitamin K is depleted. Since vitamin K is essential to the nervous system and plays important roles in protecting against bone loss and calcification of the peripheral soft tissues, its deficiency results in the symptoms associated with hypervitaminosis D. This hypothesis is circumstantially supported by the observation that animals deficient in vitamin K or vitamin K-dependent proteins exhibit remarkable similarities to animals fed toxic doses of vitamin D, and the observation that vitamin D and the vitamin K-inhibitor Warfarin have similar toxicity profiles and exert toxicity synergistically when combined. The hypothesis further proposes that vitamin A protects against the toxicity of vitamin D by decreasing the expression of vitamin K-dependent proteins and thereby exerting a vitamin K-sparing effect. If animal experiments can confirm this hypothesis, the models by which the maximum safe dose is determined would need to be revised. Physicians and other health care practitioners would be able to treat patients with doses of vitamin D that possess greater therapeutic value than those currently being used while avoiding the risk of adverse effects by administering vitamin D together with vitamins A and K.
Collapse
Affiliation(s)
- Christopher Masterjohn
- Weston A. Price Foundation, 4200 Wisconsin Ave., NW, Washington, DC 20016, United States.
| |
Collapse
|
171
|
Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006; 12:6222s-6230s. [PMID: 17062705 DOI: 10.1158/1078-0432.ccr-06-0843] [Citation(s) in RCA: 381] [Impact Index Per Article: 21.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Bisphosphonates are currently the most important class of antiresorptive agents used in the treatment of metabolic bone diseases, including tumor-associated osteolysis and hypercalcemia. These compounds have high affinity for calcium ions and therefore target bone mineral, where they are internalized by bone-resorbing osteoclasts and inhibit osteoclast function. EXPERIMENTAL DESIGN This article reviews the pharmacology of bisphosphonates and the relationship between chemical structure and antiresorptive potency. We also describe new insights into their intracellular molecular mechanisms of action, methods for assessing the effects of bisphosphonates on protein prenylation, and their potential as direct antitumor agents. RESULTS Nitrogen-containing bisphosphonates act intracellularly by inhibiting farnesyl diphosphate synthase, an enzyme of the mevalonate pathway, thereby preventing prenylation of small GTPase signaling proteins required for normal cellular function. Inhibition of farnesyl diphosphate synthase also seems to account for their antitumor effects observed in vitro and for the activation of gamma,delta T cells, a feature of the acute-phase response to bisphosphonate treatment in humans. Bisphosphonates that lack a nitrogen in the chemical structure do not inhibit protein prenylation and have a different mode of action that seems to involve primarily the formation of cytotoxic metabolites in osteoclasts. CONCLUSIONS Bisphosphonates are highly effective inhibitors of bone resorption that selectively affect osteoclasts in vivo but could also have direct effects on other cell types, such as tumor cells. After >30 years of clinical use, their molecular mechanisms of action on osteoclasts are finally becoming clear but their exact antitumor properties remain to be clarified.
Collapse
Affiliation(s)
- Anke J Roelofs
- Bone Research Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
| | | | | | | |
Collapse
|
172
|
Sen SE, Hitchcock JR, Jordan JL, Richard T. Juvenile hormone biosynthesis in M. sexta: substrate specificity of insect prenyltransferase utilizing homologous diphosphate analogs. INSECT BIOCHEMISTRY AND MOLECULAR BIOLOGY 2006; 36:827-34. [PMID: 17046596 DOI: 10.1016/j.ibmb.2006.08.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2006] [Accepted: 08/04/2006] [Indexed: 05/12/2023]
Abstract
Analogs of dimethylallyl diphosphate (DMAPP) and geranyl diphosphate (GPP) were prepared and tested as potential substrates of prenyltransferase of the tobacco hornworm, Manduca sexta, and of a sesquiterpene synthase derived from pig liver. Enzyme derived from corpora allata homogenates of both the larval and adult stage of M. sexta coupled each of the DMAPP analogs to produce homologous geranyl and farnesyl diphosphate products in the order (Z)-3-ethyl>(Z)-3-n-propyl>(Z)-3-methyl (DMAPP)>(Z)-3-i-propyl(Z)-3-n-butyl. In competition studies, the ethyl and n-propyl analogs either enhanced or had no effect on DMAPP coupling, whereas the larger analogs were inhibitors. (Z)-7-ethyl and (2Z,6Z)-3,7-diethyl analogs of GPP were as good, if not better substrates of larval prenyltransferase, while the C-3 ethyl analog of GPP, which is precursor to an isomeric form of juvenile hormone (JH) that is not typically found in insects, was poorly coupled by the enzyme. While similarities were seen for whole-cell extracts derived from adult and larval M. sexta, adult prenyltransferase derived from cytosolic and 16,000xg pellet fractions displayed distinct competitive coupling of GPP and its homologs, suggesting differences in substrate specificity as a result of enzyme localization. In contrast to M. sexta, the pig liver enzyme poorly coupled each of the homologous DMAPP derivatives, and the homologous derivatives of GPP were less efficiently coupled than GPP. These results indicate that prenyltransferase in M. sexta possesses high steric latitude at the (Z)-C-3 and C-7 alkyl positions of DMAPP and GPP, respectively, in contrast to other animal prenyltransferases but in keeping with the enzyme's presumptive role in homologous JH metabolism.
Collapse
Affiliation(s)
- Stephanie E Sen
- Department of Chemistry, Indiana University Purdue University Indianapolis (IUPUI), 402 North Blackford Street, Indianapolis, IN 46202, USA.
| | | | | | | |
Collapse
|
173
|
Thompson K, Rogers MJ. Bisphosphonates and γδ t-cells: New insights into old drugs. ACTA ACUST UNITED AC 2006. [DOI: 10.1138/20060224] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
174
|
Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RGG, Oppermann U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 2006; 103:7829-34. [PMID: 16684881 PMCID: PMC1472530 DOI: 10.1073/pnas.0601643103] [Citation(s) in RCA: 404] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2005] [Indexed: 01/05/2023] Open
Abstract
Osteoporosis and low bone mass are currently estimated to be a major public health risk affecting >50% of the female population over the age of 50. Because of their bone-selective pharmacokinetics, nitrogen-containing bisphosphonates (N-BPs), currently used as clinical inhibitors of bone-resorption diseases, target osteoclast farnesyl pyrophosphate synthase (FPPS) and inhibit protein prenylation. FPPS, a key branchpoint of the mevalonate pathway, catalyzes the successive condensation of isopentenyl pyrophosphate with dimethylallyl pyrophosphate and geranyl pyrophosphate. To understand the molecular events involved in inhibition of FPPS by N-BPs, we used protein crystallography, enzyme kinetics, and isothermal titration calorimetry. We report here high-resolution x-ray structures of the human enzyme in complexes with risedronate and zoledronate, two of the leading N-BPs in clinical use. These agents bind to the dimethylallyl/geranyl pyrophosphate ligand pocket and induce a conformational change. The interactions of the N-BP cyclic nitrogen with Thr-201 and Lys-200 suggest that these inhibitors achieve potency by positioning their nitrogen in the proposed carbocation-binding site. Kinetic analyses reveal that inhibition is competitive with geranyl pyrophosphate and is of a slow, tight binding character, indicating that isomerization of an initial enzyme-inhibitor complex occurs with inhibitor binding. Isothermal titration calorimetry indicates that binding of N-BPs to the apoenzyme is entropy-driven, presumably through desolvation entropy effects. These experiments reveal the molecular binding characteristics of an important pharmacological target and provide a route for further optimization of these important drugs.
Collapse
Affiliation(s)
- Kathryn L. Kavanagh
- Structural Genomics Consortium, University of Oxford, Oxford OX3 7LD, United Kingdom
| | - Kunde Guo
- Structural Genomics Consortium, University of Oxford, Oxford OX3 7LD, United Kingdom
| | - James E. Dunford
- Structural Genomics Consortium, University of Oxford, Oxford OX3 7LD, United Kingdom
- Bone Research Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom; and
- Nuffield Department of Orthopaedic Surgery, Oxford University, Institute of Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, United Kingdom
| | - Xiaoqiu Wu
- Structural Genomics Consortium, University of Oxford, Oxford OX3 7LD, United Kingdom
| | - Stefan Knapp
- Structural Genomics Consortium, University of Oxford, Oxford OX3 7LD, United Kingdom
| | | | - Michael J. Rogers
- Bone Research Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom; and
| | - R. Graham G. Russell
- Nuffield Department of Orthopaedic Surgery, Oxford University, Institute of Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, United Kingdom
| | - Udo Oppermann
- Structural Genomics Consortium, University of Oxford, Oxford OX3 7LD, United Kingdom
| |
Collapse
|
175
|
Kavanagh KL, Dunford JE, Bunkoczi G, Russell RGG, Oppermann U. The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. J Biol Chem 2006; 281:22004-22012. [PMID: 16698791 DOI: 10.1074/jbc.m602603200] [Citation(s) in RCA: 117] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Modification of GTPases with isoprenoid molecules derived from geranylgeranyl pyrophosphate or farnesyl pyrophosphate is an essential requisite for cellular signaling pathways. The synthesis of these isoprenoids proceeds in mammals through the mevalonate pathway, and the final steps in the synthesis are catalyzed by the related enzymes farnesyl pyrophosphate synthase and geranylgeranyl pyrophosphate synthase. Both enzymes play crucial roles in cell survival, and inhibition of farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates is an established concept in the treatment of bone disorders such as osteoporosis or certain forms of cancer in bone. Here we report the crystal structure of human geranylgeranyl pyrophosphate synthase, the first mammalian ortholog to have its x-ray structure determined. It reveals that three dimers join together to form a propeller-bladed hexameric molecule with a mass of approximately 200 kDa. Structure-based sequence alignments predict this quaternary structure to be restricted to mammalian and insect orthologs, whereas fungal, bacterial, archaeal, and plant forms exhibit the dimeric organization also observed in farnesyl pyrophosphate synthase. Geranylgeranyl pyrophosphate derived from heterologous bacterial expression is tightly bound in a cavity distinct from the chain elongation site described for farnesyl pyrophosphate synthase. The structure most likely represents an inhibitory complex, which is further corroborated by steady-state kinetics, suggesting a possible feedback mechanism for regulating enzyme activity. Structural comparisons between members of this enzyme class give deeper insights into conserved features important for catalysis.
Collapse
Affiliation(s)
- Kathryn L Kavanagh
- Structural Genomics Consortium, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom.
| | - James E Dunford
- Structural Genomics Consortium, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom; Institute of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford OX3 7LD, United Kingdom
| | - Gabor Bunkoczi
- Structural Genomics Consortium, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom
| | - R Graham G Russell
- Institute of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford OX3 7LD, United Kingdom
| | - Udo Oppermann
- Structural Genomics Consortium, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom.
| |
Collapse
|
176
|
Abstract
The discovery and development of the bisphosphonates (BPs) as a major class of drugs for the treatment of bone diseases has been a fascinating journey that is still not over. In clinical medicine, several BPs are established as the treatments of choice for various diseases of excessive bone resorption, including Paget's disease of bone, myeloma and bone metastases, and osteoporosis. Bisphosphonates are chemically stable analogues of inorganic pyrophosphate, and are resistant to breakdown by enzymatic hydrolysis. Bisphosphonates inhibit bone resorption by being selectively taken up and adsorbed to mineral surfaces in bone, where they interfere with the action of the bone-resorbing osteoclasts. Bisphosphonates are internalized by osteoclasts and interfere with specific biochemical processes. Bisphosphonates can be classified into at least two groups with different molecular modes of action. The simpler non-nitrogen-containing bisphosphonates (such as clodronate and etidronate) can be metabolically incorporated into nonhydrolyzable analogues of adenosine triphosphate (ATP) that may inhibit ATP-dependent intracellular enzymes. The more potent, nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate, and zoledronate) are not metabolized in this way but can inhibit enzymes of the mevalonate pathway, thereby preventing the biosynthesis of isoprenoid compounds that are essential for the posttranslational modification of small GTP-binding proteins (which are also GTPases) such as rab, rho, and rac. The inhibition of protein prenylation and the disruption of the function of these key regulatory proteins explain the loss of osteoclast activity and induction of apoptosis. The key target for bisphosphonates is farnesyl pyrophosphate synthase (FPPS) within osteoclasts, and the recently elucidated crystal structure of this enzyme reveals how BPs bind to and inhibit at the active site via their critical N atoms. In conclusion, bisphosphonates are now established as an important class of drugs for the treatment of many bone diseases, and their mode of action is being unraveled. As a result their full therapeutic potential is gradually being realized.
Collapse
Affiliation(s)
- R Graham G Russell
- The Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Headington, Oxford, OX3 7LD, UK.
| |
Collapse
|